Prof David Bowtell
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
536 Scholarly works
61 Projects
HIGHLIGHTS
2026
Research grants (ARC, NHMRC, MRFF)
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12022
Research grants (ARC, NHMRC, MRFF)
Driving Improvements in Ovarian Cancer Survival Through Molecular and Clinical Studies
2020
Research grants (ARC, NHMRC, MRFF)
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2017
Journal article
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
DOI: 10.1158/2159-8290.CD-17-04192016
Journal article
Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patients
DOI: 10.1158/1078-0432.CCR-15-1931
RECENT SCHOLARLY WORKS
2026
Journal article
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
DOI: 10.1038/s41467-026-71134-32026
Journal article
Using polygenic risk scores to refine risk and outcomes in high-grade serous ovarian cancer in Australia.
DOI: 10.1158/1055-9965.EPI-25-18822026
Journal article
16P Integrative proteogenomics reveals survival-linked co-expression modules and an HR activity signature in high-grade serous ovarian cancer
DOI: 10.1016/j.esmoop.2026.1080412026
Journal article
FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
DOI: 10.1200/jco.2026.44.16_suppl.30722026
Journal article
IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
DOI: 10.1200/jco.2026.44.16_suppl.55872026
Journal article
Rethinking ovarian cancer III: the past decade and future directions
DOI: 10.1038/s41568-026-00916-02026
Journal article
Abstract 6261: Inflammation-related exposures and histotype- specific ovarian cancer risk in the Ovarian Cancer Association Consortium (OCAC).
DOI: 10.1158/1538-7445.am2026-62612026
Journal article
Real-world comparative outcomes of neoadjuvant chemotherapy with interval cytoreductive surgery versus primary cytoreductive surgery in epithelial ovarian cancer: insights from the australian ovarian cancer study (AOCS)
DOI: 10.1016/j.ijgc.2025.103076